03 October 2023
03 October 2023
Clinical Trials Arena updates its exclusive DCT Tracker with a spotlight on DCT completion status over the past decade.
Syndax has confirmed that its AUGMENT-101 trial has seen success with a complete remission, or a complete remission with a partial haematological recovery, rate of 23%.
The treatment caused a 'statistically significant' decline in bile alcohols in cerebrotendinous xanthomatosis patients.
The study is a scaled-down version of the ‘gold standard’ Covid-19 infection study conducted in the UK during the pandemic.
The trial will analyse the safety, pharmacokinetics and tolerability of BI 771716 in patients aged 50 years and older.
Based on the Phase IIb trial data, the company plans to progress the antibiotic candidate to Phase III trials more quickly.
The anthracycline candidate already demonstrated positive results from the first portion of the study.
The trial will assess the safety and efficacy of oral simufilam for dementia associated with Alzheimer’s.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
